title: Behavioral effects of the novel cannabinoid full agonist AM 411.
abstract: AM 411 ((-)-1-adamantyl-Delta8-tetrahydrocannabinol) is a novel full agonist at cannabinoid CB1 receptors. The present studies were conducted to provide behavioral characterization of this compound in rats. It was hypothesized that AM 411 should produce behavioral effects similar to known cannabinoid agonists, and that these effects should be inhibited by co-treatment with a CB1 antagonist. In Experiments 1 and 2, AM 411 dose-dependently produced behaviors consistent with CB1 agonism, including analgesia, hypothermia, catalepsy and reductions in locomotion, which were blocked by a CB1-selective antagonist. In Experiment 3, AM 411 produced a dose-dependent suppression of lever-pressing on a fixed-ratio 5 (FR5) schedule, a task known to be sensitive to administration of CB1 agonists. Detailed analysis of the temporal patterns of operant responding showed that AM 411 altered the distribution of interresponse times. Experiment 4 showed that AM 411 decreased relative interior activity in the open field, which is suggestive of an anxiogenic effect. It is concluded that AM 411 produces CB1 agonist-like behavior with potency between that of WIN 55,212-2 and AM 356. AM 411 could be a useful tool for understanding the behavioral and neural effects of CB1 receptor stimulation.
authors.affiliation: Department of Psychology, University of Connecticut, 406 Babbidge Rd. Storrs, CT, 06269-1020, USA.
authors.forename: Peter J
authors.initials: PJ
authors.lastname: McLaughlin
authors.forename: Dai
authors.initials: D
authors.lastname: Lu
authors.forename: Keisha M
authors.initials: KM
authors.lastname: Winston
authors.forename: Ganesh
authors.initials: G
authors.lastname: Thakur
authors.forename: Lynn A
authors.initials: LA
authors.lastname: Swezey
authors.forename: Alexandros
authors.initials: A
authors.lastname: Makriyannis
authors.forename: John D
authors.initials: JD
authors.lastname: Salamone
mesh_terms: D000218:Adamantane / Q000031:analogs & derivatives* / Q000494:pharmacology; D000818:Animals; D002186:Cannabinoids / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D013759:Dronabinol / Q000031:analogs & derivatives* / Q000494:pharmacology; D008297:Male; D009043:Motor Activity / Q000187:drug effects* / Q000502:physiology; D010147:Pain Measurement / Q000187:drug effects* / Q000379:methods; D051381:Rats; D017207:Rats, Sprague-Dawley; D011930:Reaction Time / Q000187:drug effects* / Q000502:physiology; D043884:Receptor, Cannabinoid, CB1 / Q000819:agonists* / Q000502:physiology
chemical_list: C496392:(-)-adamantyl-delta8-tetrahydrocannabinol; D002186:Cannabinoids; D043884:Receptor, Cannabinoid, CB1; D013759:Dronabinol; D000218:Adamantane